GPT and Hypercholesterolemia: Five (12.5%) patients experienced at least one TRAE leading to a reduction in the dose frequency of famitinib, including increased alanine aminotransferase, hypercholesterolemia, hypertriglyceridemia, PPE syndrome, decreased white blood cell count, and proteinuria (n = 1 for each, 2.5%).